GSK-3β Allosteric Inhibition: A Dead End or a New Pharmacological Frontier?
Most kinase inhibitors are designed to bind to highly homologous ATP-binding sites, which leads to promiscuity and possible off-target effects. Allostery is an alternative approach to pursuing selectivity. However, allostery is difficult to exploit due to the wide variety of underlying mechanisms an...
Main Authors: | Beatrice Balboni, Mirco Masi, Walter Rocchia, Stefania Girotto, Andrea Cavalli |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-04-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/24/8/7541 |
Similar Items
-
Identification of Novel GSK-3β Hits Using Competitive Biophysical Assays
by: Beatrice Balboni, et al.
Published: (2022-03-01) -
Novel Insights into RAD52’s Structure, Function, and Druggability for Synthetic Lethality and Innovative Anticancer Therapies
by: Beatrice Balboni, et al.
Published: (2023-03-01) -
Pharmacology of Free Fatty Acid Receptors and Their Allosteric Modulators
by: Manuel Grundmann, et al.
Published: (2021-02-01) -
Navigating the Frontiers of Machine Learning in Neurodegenerative Disease Therapeutics
by: Yoonjeong Cha, et al.
Published: (2024-01-01) -
New frontiers in scientific discovery : commemorating the life and work of zdzislaw pawlak /
by: Orlowska, E.
Published: (2007)